

# Michael T Milano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1761476/publications.pdf>

Version: 2024-02-01

150  
papers

6,232  
citations

66343

42  
h-index

74163

75  
g-index

151  
all docs

151  
docs citations

151  
times ranked

6645  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oligometastases Treated With Stereotactic Body Radiotherapy: Long-Term Follow-Up of Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 878-886.	0.8	396
2	An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 346-355.	2.6	377
3	A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. <i>Cancer</i> , 2008, 112, 650-658.	4.1	240
4	Stereotactic Body Radiation Therapy (SBRT) for lung metastases. <i>Acta Oncologica</i> , 2006, 45, 808-817.	1.8	220
5	Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 793-798.	0.8	218
6	Changes in Relative Cerebral Blood Volume 1 Month after Radiation-Temozolomide Therapy Can Help Predict Overall Survival in Patients with Glioblastoma. <i>Radiology</i> , 2010, 256, 575-584.	7.3	167
7	Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 68-86.	0.8	164
8	Normal Tissue Tolerance Dose Metrics for Radiation Therapy of Major Organs. <i>Seminars in Radiation Oncology</i> , 2007, 17, 131-140.	2.2	154
9	Patient Exposure from Radiologic and Nuclear Medicine Procedures in the United States: Procedure Volume and Effective Dose for the Period 2006-2016. <i>Radiology</i> , 2020, 295, 418-427.	7.3	150
10	Malignant Pleural Mesothelioma: A Population-Based Study of Survival. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1841-1848.	1.1	141
11	Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 601-608.	2.5	137
12	Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1357-1366.	0.8	134
13	Stereotactic Body Radiotherapy for Treatment of Adrenal Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 71-75.	0.8	130
14	Descriptive Analysis of Oligometastatic Lesions Treated With Curative-Intent Stereotactic Body Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1516-1522.	0.8	129
15	Patterns and Timing of Recurrence After Temozolomide-Based Chemoradiation for Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1147-1155.	0.8	129
16	Stereotactic Body Radiotherapy for Pulmonary Metastases From Soft-Tissue Sarcomas: Excellent Local Lesion Control and Improved Patient Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 940-945.	0.8	127
17	Primary spinal cord glioma: a Surveillance, Epidemiology, and End Results database study. <i>Journal of Neuro-Oncology</i> , 2010, 98, 83-92.	2.9	122
18	Solid Tumors After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3807-3814.	1.6	122

#	ARTICLE	IF	CITATIONS
19	Normal tissue toxicity after small field hypofractionated stereotactic body radiation. <i>Radiation Oncology</i> , 2008, 3, 36.	2.7	110
20	Stereotactic Hypofractionated Radiation Therapy as a Bridge to Transplantation for Hepatocellular Carcinoma: Clinical Outcome and Pathologic Correlation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 895-900.	0.8	108
21	Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3105-3115.	1.6	107
22	Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 124-136.	0.8	105
23	Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. <i>Acta Oncologica</i> , 2012, 51, 575-583.	1.8	102
24	Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. <i>PLoS ONE</i> , 2018, 13, e0195149.	2.5	99
25	Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 87-99.	0.8	86
26	Analysis of Patients With Oligometastases Undergoing Two or More Curative-Intent Stereotactic Radiotherapy Courses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 832-837.	0.8	82
27	Long-Term Survival Among Patients With Hodgkin's Lymphoma Who Developed Breast Cancer: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 5088-5096.	1.6	82
28	Radical Irradiation of Extracranial Oligometastases. <i>Journal of Clinical Oncology</i> , 2014, 32, 2902-2912.	1.6	82
29	Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade. <i>Radiotherapy and Oncology</i> , 2019, 131, 45-51.	0.6	81
30	Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2009, 91, 301-306.	0.6	76
31	NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1007-1007.	1.6	75
32	Stereotactic radiosurgery for glioblastoma: retrospective analysis. <i>Radiation Oncology</i> , 2009, 4, 11.	2.7	73
33	Patterns of Recurrence After Curative-Intent Radiation for Oligometastases Confined to One Organ. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 157-163.	1.3	66
34	Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer. <i>Radiation Oncology</i> , 2011, 6, 80.	2.7	65
35	Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 53-67.	0.8	62
36	Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases. <i>JAMA Oncology</i> , 2021, 7, 845.	7.1	56

#	ARTICLE	IF	CITATIONS
37	Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy: Normal tissue dose constraints of the central nervous system. <i>Cancer Treatment Reviews</i> , 2011, 37, 567-578.	7.7	52
38	Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 172-187.	0.8	52
39	Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. <i>Journal of Neuro-Oncology</i> , 2016, 129, 251-258.	2.9	49
40	Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: A population-based study of 28,844 patients. <i>Cancer</i> , 2014, 120, 2334-2342.	4.1	47
41	Stereotactic Body Radiotherapy for Oligometastasis. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 247-256.	2.0	46
42	Survival after second primary lung cancer. <i>Cancer</i> , 2011, 117, 5538-5547.	4.1	42
43	Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. <i>Journal of Thoracic Disease</i> , 2014, 6, 369-74.	1.4	42
44	Second primary lung cancer after head and neck squamous cell cancer: Population-based study of risk factors. <i>Head and Neck</i> , 2012, 34, 1782-1788.	2.0	39
45	Radiotherapy for Oligometastatic Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 210.	2.8	38
46	Non-Small-Cell Lung Cancer After Breast Cancer: A Population-Based Study of Clinicopathologic Characteristics and Survival Outcomes in 3529 Women. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1081-1090.	1.1	36
47	Stereotactic Body Radiotherapy for Lung Metastases from Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 53-58.	1.3	34
48	Radiation-Induced Edema After Single-Fraction or Multifraction Stereotactic Radiosurgery for Meningioma: A Critical Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 344-357.	0.8	33
49	Nodular Leptomeningeal Disease—A Distinct Pattern of Recurrence After Postresection Stereotactic Radiosurgery for Brain Metastases: A Multi-institutional Study of Interobserver Reliability. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 579-586.	0.8	30
50	New prospects for management and treatment of inoperable and recurrent skull base meningiomas. <i>Journal of Neuro-Oncology</i> , 2008, 86, 109-122.	2.9	29
51	Chest Wall Toxicity After Stereotactic Body Radiation Therapy: A Pooled Analysis of 57 Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 843-850.	0.8	29
52	Stereotactic Body Radiation for the Spine. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 630-636.	1.3	28
53	Multicentre results of stereotactic body radiotherapy for secondary liver tumours. <i>Hpb</i> , 2013, 15, 851-857.	0.3	28
54	Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes. <i>Journal of Neuro-Oncology</i> , 2014, 116, 325-331.	2.9	28

#	ARTICLE	IF	CITATIONS
55	Thoracic malignant solitary fibrous tumors: A population-based study of survival. <i>Journal of Thoracic Disease</i> , 2011, 3, 99-104.	1.4	28
56	Impact of radiotherapy on laryngeal cancer survival. <i>Cancer</i> , 2012, 118, 1276-1287.	4.1	27
57	Oligometastases: history of a hypothesis. <i>Annals of Palliative Medicine</i> , 2021, 10, 5923-5930.	1.2	26
58	NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1117-TPS1117.	1.6	26
59	Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 1903-1910.	1.4	25
60	Stereotactic Body Radiation Therapy for Spinal Metastases: Tumor Control Probability Analyses and Recommended Reporting Standards. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 112-123.	0.8	25
61	The integration of cancer survivorship training in the curriculum of hematology/oncology fellows and radiation oncology residents. <i>Journal of Cancer Survivorship</i> , 2014, 8, 167-172.	2.9	22
62	Radiotherapy for Brain Metastases From Renal Cell Carcinoma in the Targeted Therapy Era. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 439-443.	1.3	21
63	SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 463-469.	1.3	21
64	Second primary head and neck cancer after Hodgkin lymphoma: A population-based study of 44,879 survivors of Hodgkin lymphoma. <i>Cancer</i> , 2015, 121, 1436-1445.	4.1	20
65	Stereotactic body radiotherapy as salvage treatment for recurrence of non-small cell lung cancer after prior surgery or radiotherapy. <i>Translational Lung Cancer Research</i> , 2018, 8, 78-87.	2.8	19
66	Executive summary from American Radium Society's appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 1728-1741.	1.2	19
67	Dose-Response Model for Chest Wall Tolerance of Stereotactic Body Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2016, 26, 129-134.	2.2	18
68	Prognostic Significance of Sites of Visceral Metastatic Disease in Prostate Cancer: A Population-based Study of 12,180 Patients. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 260-267.	1.9	17
69	A Primer on Dose-Response Data Modeling in Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 11-20.	0.8	17
70	Split-Course Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 185-190.	1.1	15
71	Incidental brain lesions in children: to treat or not to treat?. <i>Journal of Neuro-Oncology</i> , 2012, 106, 589-594.	2.9	15
72	A population-based study of prognosis and survival in patients with second primary thyroid cancer after Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1180-1187.	1.3	15

#	ARTICLE	IF	CITATIONS
73	Review of thoracic reirradiation with stereotactic body radiation therapy. <i>Practical Radiation Oncology</i> , 2018, 8, 251-265.	2.1	15
74	Second Primary Non-Small-Cell Lung Cancer After Head and Neck Cancer: A Population-Based Study of Clinical and Pathologic Characteristics and Survival Outcomes in 3597 Patients. <i>Clinical Lung Cancer</i> , 2020, 21, 195-203.	2.6	15
75	Spurious progression in pediatric brain tumors. <i>Journal of Neuro-Oncology</i> , 2012, 107, 651-657.	2.9	14
76	Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease. <i>Journal of Neuro-Oncology</i> , 2015, 125, 411-418.	2.9	14
77	Comparison between closed pleural biopsy and medical thoracoscopy for the diagnosis of undiagnosed exudative pleural effusions: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2020, 9, 446-458.	2.8	14
78	Stereotactic radiosurgery for spinal metastases: Case report and review of treatment options. <i>Bone</i> , 2009, 45, 817-821.	2.9	13
79	Meningioma in Breast Cancer Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 11-16.	1.3	13
80	Age and Racial Differences among PSA-Detected (AJCC Stage I-T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men. <i>Frontiers in Oncology</i> , 2013, 3, 312.	2.8	12
81	Severe radiation-induced leukoencephalopathy: Case report and literature review. <i>Advances in Radiation Oncology</i> , 2016, 1, 17-20.	1.2	12
82	Inoperable Pulmonary Carcinoid Tumors: Local Control Rates With Stereotactic Body Radiotherapy/Hypofractionated RT With Image-Guided Radiotherapy. <i>Clinical Lung Cancer</i> , 2019, 20, e284-e290.	2.6	12
83	Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24,900 Survivors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa017.	2.9	12
84	Primary Hypothyroidism in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.8	12
85	Stereotactic Radiosurgery for Vestibular Schwannomas: Tumor Control Probability Analyses and Recommended Reporting Standards. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 100-111.	0.8	12
86	Immunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: An analysis of the National Cancer Database. <i>Radiotherapy and Oncology</i> , 2019, 138, 75-79.	0.6	11
87	The Impact of Timing of Concurrent Chemoradiation in Patients With High-Grade Glioma in the Era of the Stupp Protocol. <i>Frontiers in Oncology</i> , 2019, 9, 186.	2.8	11
88	Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. <i>Practical Radiation Oncology</i> , 2020, 10, 324-329.	2.1	11
89	Spinal Drop Metastasis in Myxopapillary Ependymoma: A Case Report and a Review of Treatment Options. <i>Rare Tumors</i> , 2014, 6, 79-82.	0.6	10
90	Pediatric Normal Tissue Effects in the Clinic (PENTEC): An International Collaboration to Assess Normal Tissue Radiation Dose-Volume-Response Relationships for Children With Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.8	10

#	ARTICLE	IF	CITATIONS
91	Definitive radiotherapy for stage I nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 5572-5579.	4.1	9
92	Three- Versus Five-Fraction Regimens of Stereotactic Body Radiotherapy for Peripheral Early-Stage Nonâ€“Small-Cell Lung Cancer: A Two-Institution Propensity Scoreâ€“Matched Analysis. <i>Clinical Lung Cancer</i> , 2018, 19, e297-e302.	2.6	9
93	Hypofractionated Stereotactic Radiotherapy for Non-breast or Prostate Cancer Oligometastases: A Tail of Survival Beyond 10 Years. <i>Frontiers in Oncology</i> , 2019, 9, 111.	2.8	9
94	A systematic review and meta-analysis of liver tumor position variability during SBRT using various motion management and IGRT strategies. <i>Radiotherapy and Oncology</i> , 2022, 166, 195-202.	0.6	9
95	The evolving role of radiotherapy in treatment of oligometastatic NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1459-1471.	2.4	8
96	Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma. <i>Anticancer Research</i> , 2020, 40, 5801-5806.	1.1	8
97	Risk of brain metastases in T1â€“3N0 NSCLC: a population-based analysis. <i>Lung Cancer Management</i> , 2020, 9, LMT25.	1.5	8
98	Stereotactic body radiotherapy in patients with multiple lung tumors: a focus on lung dosimetric constraints. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 959-969.	2.4	7
99	Patient Radiation Exposure: Imaging During Radiation Oncology Procedures: Executive Summary of NCRP Report No. 184. <i>Journal of the American College of Radiology</i> , 2020, 17, 1176-1182.	1.8	7
100	NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS1098-TPS1098.	1.6	7
101	Variables affecting survival after second primary lung cancer: A population-based study of 187 Hodgkin's lymphoma patients. <i>Journal of Thoracic Disease</i> , 2012, 4, 22-9.	1.4	7
102	Single-Fraction Radiosurgery Using Conservative Doses for Brain Metastases: Durable Responses in Select Primaries With Limited Toxicity. <i>Neurosurgery</i> , 2018, 83, 437-444.	1.1	6
103	A registry-based analysis of survival outcomes in mast cell leukemia. <i>Leukemia Research</i> , 2019, 78, 24-28.	0.8	6
104	Reducing Radiation-Induced Cognitive Toxicity: Sparing the Hippocampus and Beyond. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1131-1136.	0.8	6
105	Repeat courses of SRS in patients initially treated with SRS alone for brain-metastatic melanoma. <i>Melanoma Management</i> , 2016, 3, 97-104.	0.5	5
106	Stereotactic body radiation therapy versus metastasectomy for oligometastases. <i>Journal of Thoracic Disease</i> , 2019, 11, 1082-1084.	1.4	5
107	Squamous cell carcinoma of the head and neck with unknown primary: trends and outcomes from a hospital-based registry. <i>Annals of Translational Medicine</i> , 2021, 9, 284-284.	1.7	5
108	Radiation Therapy in the Management of Patients With Limited Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 208-214.	1.3	4

#	ARTICLE	IF	CITATIONS
109	Signals from SABR-COMET time to move on to phase III studies. <i>Annals of Translational Medicine</i> , 2019, 7, S316-S316.	1.7	4
110	Treatment completion, treatment compliance and outcomes of old and very old patients treated by dose adapted stereotactic ablative radiotherapy (SABR) for T1-T3N0M0 non-small cell lung cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 442-448.	1.0	4
111	Time to treatment initiation and outcomes in high-grade glioma patients in rehabilitation: a retrospective cohort study. <i>CNS Oncology</i> , 2020, 9, CNS64.	3.0	4
112	New dosimetric guidelines for linear Boltzmann transport equations through comparative evaluation of stereotactic body radiation therapy for lung treatment planning. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 115-124.	1.9	4
113	Oligometastases to the liver: predicting outcomes based upon radiation sensitivity. <i>Journal of Thoracic Disease</i> , 2016, 8, E1384-E1386.	1.4	3
114	The correlation of fractional anisotropy parameters with Ki-67 index, and the clinical implication in grading of non-enhancing gliomas and neuronal-glioma tumors. <i>Magnetic Resonance Imaging</i> , 2020, 65, 129-135.	1.8	3
115	Survival of Patients With Second Primary Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 316-323.e2.	0.4	3
116	Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors <i>In Vivo</i> . <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6039-6055.	6.4	3
117	Survival after subsequent non-Hodgkin's lymphoma and non-small cell lung cancer in patients with malignant thymoma. <i>Journal of Thoracic Disease</i> , 2016, 8, 3605-3613.	1.4	2
118	Second primary breast cancer after diagnosis of breast cancer among male patients: An examination of population characteristics and overall survival. <i>EClinicalMedicine</i> , 2020, 27, 100551.	7.1	2
119	NRG BR002: A phase I/II trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS1105-TPS1105.	1.6	2
120	Dose-Volume Predictors of Radiation Pneumonitis After Lung Stereotactic Body Radiation Therapy (SBRT): Implications for Practice and Trial Design. <i>Cureus</i> , 2020, 12, e10808.	0.5	2
121	Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy?. <i>Journal of the National Cancer Institute</i> , 2023, 115, 605-607.	6.3	2
122	Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas. <i>Radiotherapy and Oncology</i> , 2022, 170, 79-88.	0.6	2
123	In Reply to Drs. Christodouleas and Marks. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1628-1629.	0.8	1
124	Second Course of Radiation for New Primary Head-and-Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 367-371.	1.3	1
125	In Regard to Rasmussen et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1153.	0.8	1
126	Long-term CT surveillance after primary lung cancer treatment captures events in all risk groups. <i>Translational Lung Cancer Research</i> , 2018, 7, S49-S53.	2.8	1



#	ARTICLE	IF	CITATIONS
127	Nivolumab without brain radiotherapy is insufficient for the treatment of most patients with brain metastases from clear cell renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S366-S366.	1.7	1
128	The IMPACT of Molecular Grading of Gliomas on Contemporary Clinical Practice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 859-862.	0.8	1
129	Defining the role of curative local therapy in oligometastatic cancer: a new era. <i>Annals of Palliative Medicine</i> , 2021, 10, 37-37.	1.2	1
130	Understanding and Predicting Radiation-Associated Normal Tissue Injury: A Global and Historical Perspective. <i>Medical Radiology</i> , 2014, , 103-121.	0.1	1
131	Second solid (SMN) and hematologic malignant neoplasms (HMN) among 24,900 United States testicular cancer survivors (TCS) after chemotherapy (CHEM), radiotherapy (RT), or surgery only (SURG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11573-11573.	1.6	1
132	Predicting intracranial progression following stereotactic radiosurgery for brain metastases: Implications for post SRS imaging. <i>Journal of Radiosurgery and SBRT</i> , 2019, 6, 179-187.	0.2	1
133	Back to the Future: Charting the Direction of Lower Grade Glioma Trials With Lessons From the Present and Past. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 30-34.	0.8	1
134	Cautioning Against Declaring Success Before the Finish Line. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 376-378.	0.8	1
135	Reply to G. Gandaglia et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 1167-1169.	1.6	0
136	Reply to S. Alane et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1285-1286.	1.6	0
137	Impact of Right-sided Primary Tumor Location Among Patients With Oligometastatic Colorectal Cancer Treated With Stereotactic Body Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1172-1175.	1.3	0
138	Pulmonary metastectomy: impact of tumor histology and size. <i>Journal of Thoracic Disease</i> , 2018, 10, 644-647.	1.4	0
139	The utilization patterns and comparative effectiveness of systemic therapy with high-dose thoracic radiotherapy or low-dose thoracic radiotherapy versus systemic therapy alone in newly diagnosed metastatic non-small cell lung cancer patients. <i>Journal of Radiation Oncology</i> , 2019, 8, 425-438.	0.7	0
140	In Regard to Soltys et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 609-611.	0.8	0
141	In Reply to Schultheiss. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1541-1543.	0.8	0
142	Late Toxicity from Hypofractionated Stereotactic Body Radiation. <i>Medical Radiology</i> , 2008, , 129-140.	0.1	0
143	Survivors of Childhood Hodgkin's Lymphoma After Treatment: Subsequent Solid Tumor Malignancies Based on Gender and Radiation Dose. <i>Pediatric Cancer</i> , 2013, , 179-192.	0.0	0
144	PSA-detected prostate cancer in the United States: A population-based study of 70,345 men with AJCC stage T1cN0M0 disease.. <i>Journal of Clinical Oncology</i> , 2013, 31, 50-50.	1.6	0

#	ARTICLE	IF	CITATIONS
145	The integration of cancer survivorship training in the curriculum of hematology/oncology fellows and radiation oncology residents.. Journal of Clinical Oncology, 2013, 31, e20667-e20667.	1.6	0
146	Cardiovascular mortality (CVM) among testicular nonseminoma (TN) survivors after chemotherapy (CHEM) or surgery (SURG).. Journal of Clinical Oncology, 2014, 32, 9593-9593.	1.6	0
147	Evidence table development as a novel teaching tool in cancer survivorship education.. Journal of Clinical Oncology, 2016, 34, 3-3.	1.6	0
148	An integrative approach to personalized cancer survivorship care at an academic medical center.. Journal of Clinical Oncology, 2017, 35, 37-37.	1.6	0
149	Clinical efficacy of tumor-treating fields for newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2019, 37, 2046-2046.	1.6	0
150	Increased risk of high-grade prostate cancer among testicular cancer survivors. PLoS ONE, 2022, 17, e0263573.	2.5	0